identifying novel digital measures for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in the person’s normal surrounding.
one year longitudinal study with approximately 2000 subjects will be conducted
Participants with neurological or immunological disorders from various countries will be screened and recruited
Participants with neurological or immunological disorders from various countries will be screened and recruited
All participants will be given a combination of 2-4 digital devices for use in their own environment for several periods
Data on fatigue, sleep, selected activities of daily living and other relevant contextual information will be collected by smartphone several times a day while using the devices
In order to establish which devices are suitable for use, complex data analysis will be performed
The devices that met the criteria will be considered for future use in clinical trials
The novel clinically validated digital endpoint will be able to:
On May 30 and 31, members of IDEA-FAST met in Kiel, Germany, to prepare for the start of the Clinical Observational Study (COS). The University Medical Centre Schleswig-Holstein as sponsor of the COS with their
IDEA-FAST will be represented at the annual IBD-DACH congress (inflammatory bowel disease, Germany, Austria, Switzerland). Professor Fai Ng is going to give a presentation on IDEA-FAST as an overview on eHealth in general and the
Dear all, With the end of 2021 and the Christmas season approaching, I am writing to express my gratitude and to congratulate you on your contributions and achievements over the past 12 months. It has
On 1st December 2021, IDEA-FAST invited its consortium members to join an internal Science Showcase. The aim of the Science Showcase was to review the Feasibility Study (FS) data and brainstorm the next analysis steps
There is a growing focus on monitoring health in uncontrolled (aka in-the-wild) settings. This is partially due to the limitations of occasional formal assessments, and to the increasing availability of off-the-shelf sensing devices and applications.
Touch data, and in particular text-entry data, has been predominantly collected in laboratory settings, under controlled conditions. While touch and text-entry data has consistently shown its potential for monitoring and detecting a variety of conditions
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
